Clinical trial NCT05525364: Hyperglycaemia In Childhood Hematologic Malignancies
Official title: Screening for Hyperglycemia in a Cohort of Pediatric Patients Followed in Hemato-oncology for Cancer (DIAB-ONCO)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus Risk
Lead sponsor: Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2022-09-01
Enrollment: 303
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Our cohort was composed of patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL).

Brief summary: BACKGROUND/AIM: Secondary forms of diabetes are often understudied and underdiagnosed in children and adolescents with cancer. The objectives of this cohort study were to study the incidence and risk factors for hyperglycaemia in leukaemia and lymphoma patients.

METHODS: The investigators retrospectively collected 15 years of data from paediatric patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL) immediately at cancer diagnosis. They studied risk factors for hyperglycaemia in univariate and multivariate analyses.

Detailed description: BACKGROUND:

Children and adolescents diagnosed with acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL) are treated with specific and individual chemotherapy protocols sometimes combined with radiotherapy and/or hematopoietic stem cell transplant (HSCT). Thanks to research initiatives allowing constant re-evaluation of these protocols, survival rate of childhood cancer exceeds 83%. However, the effectiveness of these treatments is not without consequences: 50% of childhood cancer survivors (CCS) develop endocrine sequelae including metabolic syndrome and glucose metabolism disorders such as diabetes, insulin resistance and impaired glucose tolerance (IGT). In the general population, diabetes confers a 2 to 3 times increased risk of cardiovascular disease and corresponds to 12-55% of cases of end-stage renal disease worldwide, being as such the 7th expected leading cause of death by 2030.

In CCS, the incidence of hyperglycaemia is still ill-defined and might range between 11 and 35% of cases. Moreover, despite the whole body of evidence that asparaginase, steroids and total body irradiation increase the risk of developing hyperglycaemia and diabetes, risk factors are missing and - asides from treatments - understudied (e.g., pre-existing obesity, sex, age, ethnicity, family history of diabetes, etc.).

AIM:

DIAB-ONCO. The purpose of this study was to assess the incidence and associated risk factors of developing hyperglycaemia in children and adolescents diagnosed with ALL, HL and NHL. Deciphering the factors associated with the onset of hyperglycaemia in paediatric patients treated for cancer will provide leverage for lifestyle or therapeutic intervention from a prevention perspective in newly diagnosed patients.

INTERVENTION:

The DIABONCO retrospective study is being carried out in collaboration with the Paediatric Haematology and Oncology (Institut Roi Albert II) of Cliniques universitaires Saint-Luc in Belgium (Brussels). The local ethical committee (Saint-Luc and UCL Hospital-Faculty Ethics Committee) approved this study protocol (approval number 2018/20MAR/122) and the study was conducted in accordance with the Declaration of Helsinki.

This investigation included patients receiving treatment protocols conferring a diabetogenic risk. This included total body, cranial and abdominal irradiation (respectively TBI, CI and AI), steroids and L-asparaginase. Our cohort was therefore composed of patients treated for acute lymphoblastic leukaemia (ALL), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). The patients were stratified according to the presence or absence of hyperglycaemia during the treatment protocol and during clinical follow-up, which ended in August 2020. The groups were called the " hyperglycaemia-positive ALL, NHL or HL " and the "hyperglycaemia-free ALL, NHL or HL".

INCLUSION and EXCLUSION CRITERIA:

All children and adolescents aged 0 to 18 years treated with the aforementioned diabetogenic treatment protocols and diagnosed at Cliniques universitaires Saint-Luc with ALL, NHL or HL between January 2004 and December 2019 were included. Patients with an incomplete file or a history of the following conditions were excluded: previous diabetes (i.e., type 1, type 2, neonatal or monogenic diabetes), pancreatitis, steatosis, Down syndrome, pancreas and liver surgery, kidney disease and previous cancer other than leukaemia and lymphoma.

Eligibility criteria: Inclusion Criteria:

* Patients admitted to hemato-onco for acute lymphoblastic leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma who are receiving treatments at diabetogenic risk for their cancer (i.e. glucocorticoids, asparaginase, total body irradiation, abdominal and/or cranial radiation)
* Age of the patient at presentation: 0 years - 18 years.

For inclusion in the "hyperglycemia cohort":

- patients under diabetogenic treatment protocols such as glucocorticoids, asparaginase, total body irradiation, abdominal and/or cranial irradiation and hyperglycemia diagnosis according to the 2014 guidelines of the International Paediatric and Adolescent Diabetes Society (ISPAD).

Exclusion Criteria:

* patients with an incomplete file
* patients with history of the following conditions: previous diabetes (i.e., type 1, type 2, neonatal or monogenic diabetes), pancreatitis, steatosis, Down syndrome, pancreas and liver surgery, kidney disease and previous cancer other than leukaemia and lymphoma.

Primary outcomes:
measure: Variables of interests - personal patient data and patient's family history
timeFrame: Through study completion, an average of two years
measure: Variables of interests - Cancer and treatment data
timeFrame: Through study completion, an average of two years
measure: Variables of interests - Blood glucose and hyperglycemia data
timeFrame: Through study completion, an average of two years
Secondary outcomes:
Other outcomes:
Locations:
city: Brussel
country: Belgium
facility: Cliniques Universitaires Saint-Luc - UCLouvain
Study officials:
affiliation: Cliniques Universitaires Saint-Luc UCLouvain
name: Philippe Lysy, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: